Teva urges Fed Circuit to save skinny label law from ‘nullification’

Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline (GSK) en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Skinny-label ruling will ‘decimate’ Hatch-Waxman, Fed Circuit told

5 January 2021 One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation.

Americas

Fed Circuit split over $235m skinny label verdict

10 August 2021 The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

Generics

Teva asks Fed Circ for ‘skinny label’ redo

12 October 2021 Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s Coreg heart drug.

More on this story

Americas

Skinny-label ruling will ‘decimate’ Hatch-Waxman, Fed Circuit told

5 January 2021 One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation.

Americas

Fed Circuit split over $235m skinny label verdict

10 August 2021 The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

Generics

Teva asks Fed Circ for ‘skinny label’ redo

More on this story

Americas

Skinny-label ruling will ‘decimate’ Hatch-Waxman, Fed Circuit told

5 January 2021 One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation.

Americas

Fed Circuit split over $235m skinny label verdict

10 August 2021 The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

Generics

Teva asks Fed Circ for ‘skinny label’ redo